The Hsp90 inhibitor has a high activity against CRC cells characterized by hyperexpression of the aforementioned chaperone; however, it may induce secondary overexpression of the cytostatic-limiting protein called survivin, leading to the development of cancer resistance to chemotherapy. Here, BIRC5 is linked to cancer.